



World Health
Organization

Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
8-10 April 2008
CCV/CICG, Geneva

Tuesday, 8 April 2008

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction		20mn
09:20	Report from IVB Director including status of implementation of recommendations Presentation: J.-M. Okwo-Bele, WHO, 20mn Discussion 20mn	FOR INFORMATION - Update on key WHO activities including on implementation of recommendations from external review of IVB advisory committees - Report to SAGE on achievement of previous recommendations	40mn
10:00	Update on developments in prequalification of vaccines and in the National Regulatory Authority assessment process Presentation: D. Wood, WHO, 20mn Discussion 40mn	FOR INFORMATION AND DISCUSSION	1hr
11:00	Coffee/tea break	Break	30mn
11:30	Priorities, major policy and implementation issues: reports from AFRO, EMRO, and SEARO Presentation: B. Masresha, AFRO, 20mn Discussion 20mn Presentation: E. Mohsni, EMRO, 20mn Discussion 20mn	FOR INFORMATION Provide SAGE with background information in defining global immunization priorities	2hrs

12:30	Lunch	Break	1hr 30mn
14:00	Priorities, major policy and implementation issues: reports from AFRO, EMRO, and SEARO (ctd.) Discussion 20mn Presentation: Dr Pem Namgyal, SEARO, 20mn Discussion 20mn		
15:00	Reports from other Advisory Committees in Immunization Advisory Committee on Polio Eradication (ACPE) report and planning for a polio review at the November 2008 SAGE meeting, S. Cochi , CDC, 15mn Discussion 15mn	FOR INFORMATION	1hr 30mn
15:30	Coffee/tea break	Break	30mn
16:00	Reports from other Advisory Committees in Immunization (ctd.) Global Advisory Committee on Vaccine Safety (GACVS) report of December 2007 meeting and agenda of June 2008 meeting Presentation: P.-H. Lambert, Chair of GACVS, 15mn Discussion 15mn Quantitative Immunization and Vaccines Related Research Advisory Committee (Quiver) meeting and related activities report, A. Hinman, Chair of Quiver 15mn Discussion 15mn		
17:00	Report from the GAVI secretariat Presentation: N. Schwalbe, GAVI, 20mn Discussion 20mn	FOR INFORMATION	40mn
18:00	Cocktail		

Wednesday, 9 April 2008

08:30	Use of polysaccharide pneumococcal vaccine Summary of the proposed updated position paper and draft recommendations	FOR DECISION -Review the evidence with respect to the following questions/issues:	2hrs
-------	---	---	------

	<p>Presentation: A. Reingold, SAGE Member and Chair of SAGE working Group, 20mn</p> <p>Discussion 1hr 40mn</p>	<ol style="list-style-type: none"> 1. Review of available data on burden of pneumococcal disease in adults and in high risk groups 2. Effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) in elderly population 3. Effectiveness of PPV23 in high risk groups 4. Safety and efficacy of repeated doses of PPV23 in older children and adults 5. Use of PPV23 to boost kids previously immunized with the 7-valent pneumococcal conjugate vaccine (PCV7) 6. Impact of giving PPV23 to pregnant women/women of reproductive age in order to prevent pneumococcal disease in infants in the first few months of life 7. Consideration of the potential use of PPV23 to mitigate pandemic influenza disease <p>-Review a draft updated vaccine position paper on the use of PPV23 and prepared by the related SAGE working group</p>	
10:30	Coffee/tea break	Break	30mn
11:00	<p>Investment case for eliminating epidemic meningitis as a public health problem in Africa</p> <p>Presentation, W. Perea, WHO, 20mn</p> <p>Discussion, 1hr 10mn</p>	<p>FOR INFORMATION AND DISCUSSION</p> <p>In November 2007, GAVI has called for an investment case on eliminating epidemic meningitis as a public health problem in Africa to be completed by June 2008</p> <p>-Review and provide guidance on a first draft investment case on control of epidemic meningitis prepared by WHO, UNICEF and partners</p>	1hr 30mn
12:30	Lunch break	Break	1hr 30mn
14:00	<p>WHO Categorization of Vaccine Preventable Diseases</p> <p>The WHO Vaccine-Preventable Disease Categorization Project: Follow-up, C. Shapiro, WHO, 20mn</p> <p>Discussion 1hr 40mn</p>	<p>FOR DECISION</p> <p>-The results of WHO's exercise to prioritize/categorize vaccine preventable diseases by public health priority, were presented at the November SAGE meeting. SAGE asked WHO to allow the experts who participated in the original exercise more</p>	2hrs

		<p>time to review and possibly revise their responses; to obtain input from additional disease experts if necessary; and to conduct the exercise at regional levels. Follow-up results will be presented, and SAGE will be asked to endorse the results of the prioritization/categorization exercise.</p> <p>-Discussion on use of the disease categorization exercise and next steps</p> <p><i>(Some results were not completed on time for the meeting and the session was limited to FOR DISCUSSION).</i></p>	
16:00	Coffee/tea break	Break	30mn
16:30	<p>Changing context of immunization financing in low and middle income countries</p> <p>Changing context of immunization financing in low income countries P. Lydon, WHO, 15mn 15mn</p> <p>Regional perspectives and way forward E. Mohsni, EMRO, 15mn</p> <p>Changing context of immunization financing in middle income countries M. Kaddar, WHO, 15mn</p> <p>Discussion 45mn</p>	<p>FOR INFORMATION AND DISCUSSION</p> <p>- To inform SAGE on latest information on immunization financing in low-income countries and issues faced in middle income countries</p> <p>- To discuss IVB strategic orientations with regards to the changing context of immunization financing and sustainability in both low and middle income countries</p>	1hr 30mn

Thursday, 10 April 2008

08:30	<p>Immunization schedules</p> <p>WHO immunization schedule G. Grant, CDC, 30mn</p> <p>Practical issues at country level in customizing an immunization schedule R. Steinglass, JSI (IMMUNIZATIONBasics), 10mn</p> <p>Discussion 1 hr 20mn</p>	<p>FOR DISCUSSION</p> <p>-As a follow-up to SAGE's request, discuss a draft revised immunization schedule building on the existing vaccine position papers and SAGE recommendations for both children and older groups.</p> <p>-Discussion on communication on and introduction of the revised immunization schedules</p>	2hrs
-------	--	--	------

		-Identify further priority research areas	
10:30	Coffee/tea break	Break	30mn
11:00	Update: WHO influenza vaccine related activities Presentation: P. Carrasco, WHO, 20mn Discussion 40mn	FOR INFORMATION -Update on WHO influenza vaccine related activities including <ol style="list-style-type: none"> 1. Results of the intergovernmental meeting: virus sharing and virus benefits 2. Progress of establishing WHO H5N1 vaccine stockpile 3. Other activities and information including on seasonal vaccine use and on testing of capacity for pandemic vaccine deployment 	1hr
12:00	Closing		30mn
12:30	End of meeting		